Clinical Trial Update: Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens [Phase 3]

View source ↗

Summary

Phase 3 trial comparing FOND to FOND+O for prevention of chemotherapy-induced nausea and vomiting in hematology patients receiving highly emetogenic regimens; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complications of Bone Marrow Transplant
• Hematologic Neoplasms

Drugs mentioned

• FOND
• FOND+O

Snippet

Sponsor: Augusta University | Conditions: Complications of Bone Marrow Transplant, Hematologic Neoplasms | Phase 3 | Status: COMPLETED | Results posted: 2018-08-20